My son is 13 years old, and he has been fighting idiopathic pulmonary hypertension with every resource and therapy existing in Australia. Despite his strength, he has exhausted all possible approaches and now is listed for a double lung transplant. There is a ray of hope in this difficult situation: a drug named 'Sotatercept'. Its potential has shown significant promise in trials, presenting a chance to delay his need for a double lung transplant. I - and many others facing this battle - am pleading for Merck to grant approval on compassionate grounds to access Sotatercept in Australia for paediatrics. This drug is approved by the FDA in the United States; however, its trials in Australia are still underway. The use of Sotatercept has demonstrated profound therapeutic effects in pulmonary hypertension patients, thus potentially improving the quality of their life and longevity significantly (Source: FDA Reports). While we understand that trials are necessary for the regular path of drug approvals, every day waiting is a day lost for patients like my son. Let's urge Merck to act humanely, to consider this plea, and authorise the compassionate use of Sotatercept for children in Australia. Your signature can make a real difference to a child's life. Sign this petition now.